Junyi Dai
CIK: 0002022463
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
INDP
Indaptus Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Dai Junyi
Dai Junyi (SEC CIK 0002022463) files insider reports with the SEC as Chief Executive Officer of Indaptus Therapeutics, Inc. (INDP).
Signal8 holds 1 ownership filing by Dai Junyi, a Form 3, filed on Apr 2, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Dai Junyi's filings is in NEW YORK, NY.
Other insiders filing for Indaptus Therapeutics, Inc. (INDP)
- Lu Qinglai, Director
- Yao Yun, 10% Owner
- SINO LION VENTURES Ltd, 10% Owner
- Lazar David E., Director
- Jabbour Jerome D, Director
- McMurdo Matthew Charles, Director